Analyst firms · Goldman Sachs · RYTM

Goldman Sachs RYTM price target and rating history

Rhythm Pharmaceuticals Inc. (RYTM) · Health Care

Goldman Sachs rates Rhythm Pharmaceuticals Inc. (RYTM) Buy with a $97 price target, as of its latest action on Jul 10, 2025. It has published 3 rating actions on RYTM since September 2021, including 1 upgrade and 0 downgrades. Across 4 firms with a RYTM price target in the last 12 months, the median target is $134.50.

Current rating
Buy
Price target
$97
Median target, all firms
$134.50
Actions on RYTM
3

Goldman Sachs price target on RYTM

$97$56$1420222023202420252026
Goldman Sachs price target on RYTM, each point a stated target, September 2021 to July 2025.

Every Goldman Sachs rating on RYTM

How other firms rate RYTM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
William BlairOutperformOct 16, 2026
Wolfe ResearchOutperformSep 17, 2026
Leerink PartnersOutperform$133Sep 14, 2026
Deutsche BankHold$120Aug 28, 2026
RBC Capital MarketsOutperform$478Feb 19, 2026
CitigroupBuy$136Nov 25, 2025

Questions about Goldman Sachs and RYTM

What is Goldman Sachs's price target for RYTM?
Goldman Sachs's latest stated price target for Rhythm Pharmaceuticals Inc. (RYTM) is $97, from its action on Jul 10, 2025.
What is Goldman Sachs's rating on RYTM?
Goldman Sachs rates RYTM Buy, a bullish rating, as of Jul 10, 2025.
When did Goldman Sachs last change its view on RYTM?
On Jul 10, 2025, Goldman Sachs starts coverage at Buy, price target $97.
How does Goldman Sachs's RYTM target compare with other analysts?
Across 4 firms with a RYTM price target in the last 12 months, the median target is $134.50.

More RYTM rating histories

All Goldman Sachs ratingsRYTM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.